2023
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
Gelissen J, Adjei N, McNamara B, Mutlu L, Harold J, Clark M, Altwerger G, Dottino P, Huang G, Santin A, Azodi M, Ratner E, Schwartz P, Andikyan V. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. Annals Of Surgical Oncology 2023, 30: 5597-5609. PMID: 37358686, DOI: 10.1245/s10434-023-13757-0.Peer-Reviewed Original ResearchConceptsHyperthermic intraperitoneal chemotherapyIntraperitoneal chemotherapyOvarian cancerStage III epithelial ovarian cancerUse of HIPECEpithelial ovarian cancerHigh-quality evidenceOvarian cancer treatmentHIPEC useInterval cytoreductionCytoreductive surgeryNeoadjuvant chemotherapyPerioperative careHIPEC protocolsHIPEC techniqueTreatment modalitiesPatient outcomesSingle administrationTumor disseminationChemotherapyCancerCancer treatmentOptimal candidatesMain siteLife data
2012
Prognostic Significance of Vascular Endothelial Growth Factor Serum Determination in Women with Ovarian Cancer
Bandiera E, Franceschini R, Specchia C, Bignotti E, Trevisiol C, Gion M, Pecorelli S, Santin AD, Ravaggi A. Prognostic Significance of Vascular Endothelial Growth Factor Serum Determination in Women with Ovarian Cancer. International Scholarly Research Notices 2012, 2012: 245756. PMID: 22792477, PMCID: PMC3390037, DOI: 10.5402/2012/245756.Peer-Reviewed Original ResearchIndependent prognostic factorPrognostic factorsPrognostic significanceOvarian cancerSerum vascular endothelial growth factor (VEGF) levelsVascular endothelial growth factor levelsPresence of ascitesLymph node involvementResidual tumor sizeSubgroup of patientsGood prognostic markerGrowth factor levelsPotential prognostic significanceMEDLINE/PubMedSVEGF levelsFIGO stageNode involvementOverall survivalTumor sizeTumor gradeEligible studiesPatient outcomesPrognostic markerInclusion criteriaPrognostic variables